International Flavors & Fragrances Inc. (IFF) Stock Price & Analysis

International Flavors & Fragrances Inc. (IFF) closed at USD 93.83 on Thursday, October 22, 2026, up 3.08% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 91.03; the Oct 22, 2026 session ranged USD 90.13–93.88 on volume of 1,930,432 shares. Market capitalization is $23.94B, with a 52-week range of USD 61.3–93.89 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/IFF.md

Key facts (IFF)

• Last four reported quarters (through Jun 30, 2026): revenue $9.98B, net income $292M (2.9% margin), free cash flow $540M (SEC filings).
• Valuation: P/E 82.0x (avg 81.1x at the last 1 fiscal year-ends), EV/EBITDA 20.6x, net debt $5.13B.
• 5 of 80 tracked superinvestors hold IFF (13F, Q2 2026): 0 new, 3 added, 1 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 3 Form 4 filings, $1.3M; 3 not under a Rule 10b5-1 plan ($1.3M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $20.3M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.10 on a 1–5 scale) (20 analysts), mean target USD 97.18 (range 76–108).
• Total return with dividends: 1Y +45.8% vs S&P 500 +14.9%; 5Y -26.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD 0.81, revenue estimate $1.91B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IFF)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (IFF)

P/E 82.0x · P/S 2.4x · EV/EBITDA 20.6x · EV/Sales 2.9x · P/FCF 44.3x · P/B 1.7x · FCF yield 2.26% · Earnings yield 1.22% · Dividend yield (paid, TTM) 1.71% · Net debt $5.13B · EV $29.1B

P/E at fiscal year-ends: Dec 2024 81.1x.

Superinvestors (SEC 13F-HR, Q2 2026) (IFF)

5 of 80 tracked investors hold IFF. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (IFF)

0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (IFF)

1 purchase, $20.3M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (IFF)

Consensus Buy (mean 2.10 on a 1–5 scale), 20 analysts; mean target USD 97.18 (low 76, high 108).

Rating changes, last 120 days:

Total return (dividends reinvested) (IFF)

IFF revenue by business segment (quarter ended Jun 30, 2026)

IFF revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

IFF customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 10% of revenue, per the company's 10-K filed Feb 27, 2026. The company does not name it.

IFF company outlook (results filed Aug 4, 2026)

• “Financial Guidance on a Continuing Operations Basis Announces Enhanced $2.5B Share Repurchase Authorization;”

Quoted word-for-word from the SEC 8-K results press release.

IFF analyst estimates and revisions

IFF options: expected move

Options price a move of about ±8.7% (±$8.18) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±8.2% on average.

30-day implied volatility 34.2% vs 19.8% realized over the last 30 trading days. Put/call ratio (volume) 2.71. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (IFF)

Nexqual's technical model rates IFF "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (IFF)

Wall Street analysts rate IFF "Buy" based on 20 analysts, with a mean price target of USD 97.18 (range USD 76–108), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (IFF)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (IFF)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financial Health Score (IFF)

Nexqual rates International Flavors & Fragrances Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.

Ownership (IFF)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (IFF)

International Flavors & Fragrances Inc. is led by Jon Erik Fyrwald, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (IFF)

Notable institutional backers of International Flavors & Fragrances Inc. include Dodge & Cox Inc., Freemont Capital Pte Ltd., First Eagle Investment Management, LLC, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From International Flavors & Fragrances Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• Consumer insights, science and creativity are at the heart of our Scent business, along with our unique portfolio of natural and synthetic ingredients, global footprint, innovative technologies and know-how, and customer intimacy.
• We have developed unique molecules and delivery systems for our customers that serve as the foundations of successful products around the world.
• Through our global network of creative centers and application laboratories, we transform the Taste, Health & Biosciences, Scent and Food Ingredients (and, prior to its disposition, Pharma Solutions) products that we have developed in the research and development process into commercially viable solutions for our customers.

Legal & Regulatory Risks (Item 1A, quoted)

• We may also be exposed to serious adverse health claims related to undetected poor quality of raw materials, internal system failures to adequately reduce or eliminate certain hazards (such as pathogens, allergens, contaminants, pesticides, physical hazards, etc.) or products that are not in line with required or agreed specifications.
• Failure to comply with environmental protection laws may cause us to close, relocate or operate one or more of our plants at reduced production levels, and expose us to civil or criminal liability, which could adversely affect our operating results and future growth.
• We could be adversely affected by violations, by us or our counterparties, of U.S. or foreign anti-bribery, international trade, anti-corruption, antitrust or competition laws and regulations, applicable sanctions or employment and human rights or employment regulations.
• We operate and may pursue opportunities in jurisdictions such as China, India, Brazil, Russia, and certain African countries, which present elevated risks of fraud, corruption, and internal control challenges.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt